Program

Sunday, November 10

Welcome and Introductons:
A Conversation and Open Forum with the Course Co-Directors

5:00 p.m.-6:00 p.m.

• Tom Curran, The Children’s Hospital of Philadelphia, Philadelphia, PA
• George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
• Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

Pre-Assessment

6:00 p.m.-6:30 p.m.

Keynote Presentation

6:30 p.m.-7:30 p.m.

Speaker to be announced

Opening Reception and Dinner

7:30 p.m.-9:30 p.m.

Monday, November 11

Continental Breakfast

Introduction to Cancer Medicine and Diagnostics

8:00 a.m.-12:00 p.m.

Overview: An introduction to clinical cancer medicine
George D. Demetri, Dana-Farber Cancer Institute, Boston, MA

Diagnostic pathology: A primer
Massimo Loda, Dana-Farber Cancer Institute, Boston, MA

Cancer imaging
Lawrence H. Schwartz, Columbia University Medical Center, New York, NY

Break

Translating biomarkers from research discoveries to validated clinical molecular diagnostic tests
Maureen Cronin, Celgene Corporation, San Francisco, CA

Lung cancer: A model for personalized cancer therapy
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

Panel Discussion and Questions: Personalized Cancer Medicine and What It Means In The Clinic

Buffet Lunch

12:00 p.m.-1:00 p.m.

Travel Time to Observational Visits

1:00 p.m.-1:30 p.m.

Off-Site Observational Visits

1:30 p.m.-4:30 p.m.

• Surgical Pathology Laboratory
• Diagnostic Radiology Laboratory

Travel Time from Observational Visits

4:30 p.m.-5:00 p.m.

One-on-One Meetings ("Office Hours")

5:15 p.m.-6:15 p.m.

Buffet Dinner

Small Group Discussion Sessions

7:00 p.m.-8:30 p.m.

Tuesday, November 12

Continental Breakfast

The Environment of Clinical Investigations

8:00 a.m.-11:00 a.m.

Human subjects considerations in translational research
Mark E. Robson, Memorial Sloan-Kettering Cancer Center, New York, NY

Clinical research: An overview
Peter C. Adamson, The Children’s Hospital of Philadelphia, Philadelphia, PA

Reviewing, approving, and managing research involving human subjects
Michele Russell-Einhorn, Dana-Farber Cancer Institute, Boston, MA

Regulatory issues and the FDA in translational research
Grant A. Williams, Williams Cancer Drug Consulting, LLC, Wayne, PA

Panel Discussion and Questions: Clinical Research

Travel Time to IRB Session / Pickup Box Lunches

11:00 a.m.-11:30 a.m.

Overview of IRB / Lunch

11:30 a.m.-12:00 p.m.

• George D. Demetri, Dana-Farber Cancer Institute, Boston, MA

Observation of Live IRB Session

12:00 p.m.-1:30 p.m.

Panel Discussion and Questions on Live IRB Session

1:45 p.m.-2:30 p.m.

Travel Time from IRB Session

2:30 p.m.-3:00 p.m.

Free Time

3:00 p.m.-3:30 p.m.

One-on-One Meetings ("Office Hours")

3:30 p.m.-5:00 p.m.

Panel Discussion: Getting Started in Translational Research

5:00 p.m.-6:00 p.m.
A basic researcher perspective on how to get started in translational research, including topics such as how to start a collaboration, assess resources, etc.

Title to be announced
Suzanne J. Baker, St. Jude’s Research Hospital, Memphis, TN

Panel Discussion and Open Forum

Buffet Dinner

6:00 p.m.-7:00 p.m.

Special Presentation

7:00 p.m.-8:30 p.m.

Concept to patient: The long road for translation of possibility into accessible reality
Joshua Boger, Vertex Pharmaceuticals Incorporated, Cambridge, MA

Reception

8:30 p.m.-9:30 p.m.

Wednesday, November 13

Continental Breakfast

7:30 a.m.-8:30 a.m.

Orientation / Questions for Cancer Patient Clinic Visits

8:30 a.m.-9:00 a.m.

• George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
• Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

Travel Time to Patient Clinic Visits
(Dana-Farber Cancer Institute, Massachusetts General Hospital)

9:00 a.m.-9:30 a.m.

Interactive Observational Visits to Cancer Patient Clinics
(Dana-Farber Cancer Institute, Massachusetts General Hospital)

9:30 a.m.-11:30 a.m.

Travel Time from Patient Clinic Visits

11:30 a.m.-12:00 p.m.

Buffet Lunch

12:00 p.m.-1:00 p.m.

The Research & Development Process

1:00 p.m.-5:00 p.m.

The story of Taxol
Susan Band Horwitz, Albert Einstein Medical College, Bronx, NY

Targeting the hedgehog pathway in cancer
Frederic de Sauvage, Genentech, Inc., South San Francisco, CA

Break

Cancer genetic dependencies targeted by small-molecule therapeutics
Stuart L. Schreiber, Broad Institute of MIT and Harvard, Cambridge, MA

Combinatorial approaches
Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA

The role of variability
Donna S. Neuberg, Dana-Farber Cancer Institute, Boston, MA

Panel Discussion and Questions: Drug Discovery and Development: The Changing Environment

Free Time

5:00 p.m.-6:00 p.m.

Dinner

Group Discussion

7:00 p.m.-8:30 p.m.

Validating preclinical therapeutic leads in BRAF mutant melanoma and raising new questions in clinical trials
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA

Title to be announced
Richard M. Marais, Paterson Institute for Cancer Research, Manchester, England

Questions and Discussion

Thursday, November 14

Continental Breakfast

7:30 a.m.-8:30 a.m.

Orientation / Questions for Cancer Patient Clinic Visits

8:30 a.m.-9:00 a.m.

• George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
• Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

Travel Time to Patient Clinic Visits
(Dana-Farber Cancer Institute, Massachusetts General Hospital)

9:00 a.m.-9:30 a.m.

Interactive Observational Visits to Cancer Patient Clinics
(Dana-Farber Cancer Institute, Massachusetts General Hospital)

9:30 a.m.-11:30 a.m.

Travel Time from Patient Clinic Visits

11:30 a.m.-12:00 p.m.

Buffet Lunch

12:00 p.m.-1:00 p.m.

Targeted Medicine

1:00 p.m.-5:00 p.m.

Immune checkpoint blockade in cancer therapy: New insights and opportunities
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

Immunotherapy/Vaccines
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA

Break

Heterogeneity in breast cancer: Relevance and therapeutic implications
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

Tumor metabolomics/IDH-1
David Schenkein, Agios Pharmaceuticals, Cambridge, MA

Additional speaker to be announced

Panel Discussion and Questions: Targeted Medicine

Free Evening / Dinner on Own

5:00 p.m.-

Friday, November 15

Continental Breakfast

7:00 a.m.-8:00 a.m.

Translating Differently

8:00 a.m.-10:15 a.m.

New insights into pediatric high-grade glioma
Suzanne J. Baker, St. Jude’s Research Hospital, Memphis, TN

Title to be announced
Jennifer R. Grandis, University of Pittsburgh, Pittsburgh, PA

Title to be announced
Olufunmilayo I. Olopade, University of Chicago, Chicago, IL

Additional speaker to be announced

Panel Discussion and Questions

Closing Summary and Observations

10:15 a.m.-11:00 a.m.

A new era in cancer therapy
Edward J. Benz, Jr., Dana-Farber Cancer Institute, Boston, MA

• Tom Curran, The Children's Hospital of Philadelphia, Philadelphia, PA
• George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
• Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

Post-Assessment

11:00 a.m.-11:30 a.m.

Departure

11:45 a.m.